The "one drug -one target -one disease" paradigm in drug discovery has been reconsidered during the last decade. This paradigm change was mainly caused by high attrition rates in drug approvals due to toxicity and lack of efficacy. Computational techniques play an important role in prediction and recognition of novel targets for approved drugs. We will discuss two machine learning approaches -self organizing maps and inverse distance weighting -for polypharmacological profiling of bioactive compounds, exemplified by two prospective studies [1, 2] .
